HER2-targeting agents (e.g., trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine (TDM-1)) are used to treat HER2-positive breast cancer and improve survival 7, 8. This evidence concerns the gene ERBB2 and breast carcinoma.